• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

F-18 FDG PET/CT对复发性多发性骨髓瘤精确定位的价值。

Value of precise localization of recurrent multiple myeloma with F-18 FDG PET/CT.

作者信息

Cholewinski Witold, Castellon Ivan, Raphael Barbara, Heiba Sherif I

机构信息

Nuclear Medicine Service, Saint Vincent's Comprehensive Cancer Center, New York, New York, USA.

出版信息

Clin Nucl Med. 2009 Jan;34(1):1-3. doi: 10.1097/RLU.0b013e31818f45ac.

DOI:10.1097/RLU.0b013e31818f45ac
PMID:19092371
Abstract

A 37-year-old man with multiple myeloma in remission underwent routine fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) study for disease restaging. Both FDG-PET and CT images showed focal abnormalities in the region of the T6 vertebra, but the fused images that are routinely provided with PET/CT could precisely localize the FDG active lesion to a soft tissue focus in the epidural space, away from a lytic nonactive vertebral body lesion despite their close proximity. The PET/CT scan identified a few other metabolically active osseous lesions out of many lytic bony changes throughout the skeleton. Accordingly, the patient received the correct management for an impending spinal cord compression at the appropriate time, in addition to systemic therapy for disease relapse.

摘要

一名处于缓解期的37岁多发性骨髓瘤男性患者接受了用于疾病再分期的常规氟脱氧葡萄糖-正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)检查。FDG-PET和CT图像均显示T6椎体区域有局灶性异常,但PET/CT常规提供的融合图像能够将FDG活性病变精确地定位到硬膜外间隙的一个软组织病灶,该病灶与一个溶骨性无活性椎体病变虽位置紧邻,但相互分离。PET/CT扫描在全身多处溶骨性骨改变中发现了其他一些代谢活跃的骨病变。因此,除了针对疾病复发的全身治疗外,患者还在适当的时候接受了针对即将发生的脊髓压迫的正确治疗。

相似文献

1
Value of precise localization of recurrent multiple myeloma with F-18 FDG PET/CT.F-18 FDG PET/CT对复发性多发性骨髓瘤精确定位的价值。
Clin Nucl Med. 2009 Jan;34(1):1-3. doi: 10.1097/RLU.0b013e31818f45ac.
2
Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.F-18氟化钠正电子发射断层显像/X线计算机体层成像(F-18 NaF PET/CT)在检测多发性骨髓瘤骨受累方面是否具有补充作用?一项F-18氟代脱氧葡萄糖正电子发射断层显像/X线计算机体层成像(F-18 FDG PET/CT)与F-18氟代脱氧葡萄糖氟化钠正电子发射断层显像/X线计算机体层成像(F-18 FDG NaF PET/CT)的对比研究。
Ann Hematol. 2015 Sep;94(9):1567-75. doi: 10.1007/s00277-015-2410-3. Epub 2015 Jun 13.
3
[F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.[F-18]氟脱氧葡萄糖正电子发射断层扫描及正电子发射断层扫描-计算机断层扫描在复发性和转移性胆管癌中的应用
J Comput Assist Tomogr. 2007 Mar-Apr;31(2):223-8. doi: 10.1097/01.rct.0000237811.88251.d7.
4
18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation.18F-FDG PET/CT 用于检测和定位干细胞移植后多发性骨髓瘤患者的残留或复发疾病。
Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):493-500. doi: 10.1007/s00259-011-1993-8. Epub 2011 Nov 24.
5
[The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].[氟脱氧葡萄糖正电子发射断层扫描在多发性骨髓瘤中的价值]
Vnitr Lek. 2006 Mar;52(3):207-14.
6
Malignant involvement of the spine: assessment by 18F-FDG PET/CT.脊柱恶性病变:18F-FDG PET/CT评估
J Nucl Med. 2004 Feb;45(2):279-84.
7
Multiple myeloma imaging.
Diagn Interv Imaging. 2013 Feb;94(2):190-2. doi: 10.1016/j.diii.2012.12.003. Epub 2013 Jan 16.
8
18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.18F-FDG PET/CT、99mTc-MIBI及MRI在多发性骨髓瘤患者评估中的应用
J Nucl Med. 2008 Feb;49(2):195-200. doi: 10.2967/jnumed.107.045641. Epub 2008 Jan 16.
9
Whole-body (18)F-FDG PET identifies high-risk myeloma.全身(18)F-FDG PET可识别高危骨髓瘤。
J Nucl Med. 2002 Nov;43(11):1457-63.
10
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.11C-胆碱与18F-氟代脱氧葡萄糖PET/CT在评估多发性骨髓瘤患者骨受累情况中的比较
World J Surg Oncol. 2007 Jun 20;5:68. doi: 10.1186/1477-7819-5-68.